Consenso de expertos españoles sobre el uso de la safinamida en la enfermedad de Parkinson

February 20, 2019

Publications

>

Article

Sí

Consenso de expertos españoles sobre el uso de la safinamida en la enfermedad de Parkinson

Publicated to:NEUROLOGIA. 36 (9): 666-672 - 2021-01-01 36(9), DOI: 10.1016/j.nrl.2018.04.007

Authors: Valldeoriola F; Grandas F; Arbelo J; Blázquez Estrada M; Calopa Garriga M; Campos-Arillo V; Garcia Ruiz P; Gómez Esteban J; Leiva Santana C; Martínez Castrillo J; Mir P; Salvador Aliaga A; Vivancos Matellano F; Yáñez Baña R

Affiliations

Complejo Hosp Univ Ourense, Serv Neurol, Orense, Spain - Author

Complejo Hospitalario Universitario de Ourense - Author

Fdn Jimenez Diaz, Serv Neurol, Madrid, Spain - Author

Hosp Clin Barcelona, Inst Neurociencies, Serv Neurol, Unitat Trastorns Moviment, Barcelona, Spain - Author

Hosp Clin Univ Valencia, Serv Neurol, Valencia, Spain - Author

Hosp Gen Alicante, Serv Neurol, Alicante, Spain - Author

Hosp Gen Univ Gregorio Maranon, Unidad Trastornos Movimiento, Madrid, Spain - Author

Hosp Insular Univ Gran Canaria, Telde, Las Palmas De G, Spain - Author

Hosp Ramon & Cajal, Serv Neurol, IRYCIS, Madrid, Spain - Author

Hosp Univ Bellvitge, Unidad Trastornos Movimiento, Serv Neurol, Lhospitalet De Llobregat, Barcelona, Spain - Author

Hosp Univ Cent Asturias, Serv Neurol, Oviedo, Asturias, Spain - Author

Hosp Univ Cruces, Inst Invest Biocruces, Yrea Enfermedades Neurodegenerat, Baracaldo, Vizcaya, Spain - Author

Hosp Univ, Serv Neurol, Unidad Trastornos Movimiento, Madrid, Spain - Author

Hosp Vithas Xanit Int Benalmadena, Benalmadena, Malaga, Spain - Author

Hospital Clinic Barcelona - Author

Hospital Clínico Universitario de Valencia - Author

Hospital de Cruces - Author

Hospital General Universitario de Alicante - Author

Hospital General Universitario Gregorio Marañón - Author

Hospital Insular, Las Palmas - Author

Hospital Ramón y Cajal - Author

Hospital Universitari de Bellvitge - Author

Hospital Universitario Central de Asturias - Author

HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO - Author

Hospital Vithas Xanit Internacional Benalmádena - Author

Univ Autonoma Madrid, Madrid, Spain - Author

Univ Seville, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla, Serv Neurol & Neurofisiol Clin,Unidad Trastornos, Seville, Spain - Author

Universidad Autónoma de Madrid - Author

Abstract

© 2018 Safinamide is a new add-on drug to levodopa for the treatment of Parkinson's disease (PD) with motor fluctuations. Due to the recent incorporation of safinamide into routine clinical practice, no post-authorisation phase IV studies on the safety of safinamide have been conducted to date. This study provides clinical management guidelines for safinamide based on the opinion of a group of experts in movement disorders. This project was developed in 2 phases: 16 local meetings in phase 1 and a national meeting in phase 2. The meetings followed a pre-established agenda. The present clinical practice guidelines are based on the main conclusions reached during the national meeting. The group concluded that safinamide is effective in reducing motor and non-motor fluctuations. PD patients with mild-to-moderate fluctuations benefit most from treatment, although the drug may also improve the clinical status of patients with advanced PD. The dose of other dopaminergic drugs may be reduced after introducing safinamide, which would contribute to reducing such adverse reactions as impulse control disorder. At doses higher than those usually prescribed, safinamide may also improve dyskinesia. The experts agreed that safinamide is well tolerated and causes few adverse reactions when compared with placebo.

Keywords

discinesiasdyskinesiaefficacyfluctuacionesfluctuationsglutamateglutamatoinhibidores de la maolevodopamao-b inhibitorsmotorparkinsonsafetysafinamidasafinamidetrialAdd-on therapyDiscinesiasDyskinesiaFluctuacionesFluctuationsGlutamateGlutamatoInhibidores de la maoMao-b inhibitorsParkinsonSafinamidaSafinamide

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal NEUROLOGIA due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2021, it was in position 46/212, thus managing to position itself as a Q1 (Primer Cuartil), in the category Clinical Neurology.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 1.42, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-18, the following number of citations:

WoS: 5
Scopus: 6

Indexed in

License and use

Citations

Altmetrics

Analysis of institutional authors

Share

Consenso de expertos españoles sobre el uso de la safinamida en la enfermedad de Parkinson

Affiliations

Abstract

Keywords

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

Impact and social visibility